the toxaglate group had a known allergic history (not to contrast medium) or asthma, whereas 77 receiving iupanfidOt had a similar history . Seven tithe 52 loeaglate-Irealed patients developed an allergic adverse reaction compared with none of the 77 in the !upamidul group (p = 0.001). Of 41 patients recrtvlag btxaglate who were prrmedirated with diphenhydomine, d had an allergic -4,-wt . lathe iopamidol group 45 patients received similar premedication and none had an allergic adverse reaction (p < 0 . 121 .
Thus, this multicenter study shows that adverse rewfiens occur more anew with tuxagtale than with iupamidet and "rat patients with an allrge hi story have a greater rids with invagtale therapy compared with iopamidol.
(J Am Call Cmdiol 1992 ;19:399-906) side effects (1, 3, 4, 11, 12) and may also play a role in allergic reactions (1 During the past 2 decades there has been an active search for new radiographic contrast compounds to eliminate the cardiovascular side effects and chemotoxicity . To decrease die osmolality of the contrast medium, an effort has been made to increasethe number of iodine atoms per osmo€ically active panicle. In 1973 ioxaglate was synthesized (18). It is a structural dinser with six iodine atoms to one anionic functional group, as compared with the conventional diatrizoate molecule . which has only three iodine atoms to one anionic group . Other efforts to reduce osmolality have led to the development of nonionic contrast media. Conventional contrast media are ionic compounds with cation and anion particles in solution ; nonionic compounds reduce their osmolality by having only one particle in solution for a given iodine content, The first noninnic contrast medium, metrizamide . was introduced in 1974 (19) . Melrzamide has two major disadvantages : it is not heat stable and not stable in solution ; therefore, it must be reconstituted from the lyophilized form immediately before intravascular injecliun . Mum recently the motivate compounds iopamidol, iohexol and ineersol have been developed and released for clinical use, These compounds are very stable in aqueous solution .
Large multicenter studies (20) (21) (22) have shown that the arsa .lo,rtsvss.eo 000TZ ET AL . ADVERST EVPNTS WITH CONTRAST MEDIA incidence of severe and moderate adverse reactions is signifeantly less with the intravenous use of the low osmolalit y nonionic contrast media than c0 he conventional high osmolality ionic contrast media . The ionic dimer ioxaglate was nut included in these multicenter trials because its intravenous use is 2=sociated with a high incidence of vomiting !20,22) ; however, ioxaglate is widely accepted for intraarterial procedures. Because the published studies (23) (24) (25) comparing the low osmolality ionic direr with nonionic contrast medium were performed at single institutions and included only a small number of patients, the true incidence ufthe adverse reactions may be questioned . Therefore, this multicenter study was performed to evaluate the adverse reactions associated with the low osmolality ionic dieter ioxaglate and the nonionic monomer ioparnidel during intraarterial cardiac and coronary injections .
Methods
Study design. The study was eta prospoelive randomized double-blind design for comparing the combination of icxaglale meglumine, 39 .3% and ioxaglate sodium, 19 .6% (Hexabrix) with iopamidol, 76% (lsovue-370) as contrast media used for left ventricuiography and selective coronary angiography . Twelve medical centers (nine in the U .S. and three in Canada) participated . Randomized lists for the two contrast media were generated by Squibb Diagnostics . The technician or nurse in the laboratory selected the contrast medium from commercially available lots . The patients, the physicians (investigators) perfuming the study and the investigators analyzing the data did not know which contrast medium was used .
Patient selection, Men or women 018 years of age who required coronary angiography and left ventriculography for clinical diagnostic evaluation were candidates for this study . Patients with the following conditions were excluded from the study: I) pregnancy, childbearing potential or current breast feeding; 2) a history of a previous reaction to radiographic contrast medium or iodine compounds ; 3) a bleeding disorder; 4) significant renal disease (serum creatinine >2 mg/dl) ; 5) phcochromocylema, sickle cell disease, multiple myeloma or parapruteinemin; 6) significant hepatic disease (bilirubin >2 mg/100 ml) ; 7) infection near the proposed site of catheter introduction ; 8) acute myocardial infarction and scheduled streptokinase therapy or percutaneous translumimd coronary angioplasty ; 9) known significant mitral or aortic valve disease; 10) significant primary cardiemyop[hy ; II) a permanent pacemaker ; 12) atrial fibrillationllulter or frequent premature atrial or ventricular depolarization (>3/min) ; 13) left bundle branch block ; 14) electrocardiographic (ECG) evidence of left ventricular hypertrophy with strain pattern ; 15) weight >160 kg ; and 16) previous entry into this study or current participation in a clinical trial of an investigational drug .
Study protocol . The protocol was approved by the Human Research Committee at each of the 12 medical centers and informed written consent was obtained from each patient before the procedure .
Procedures . A brief cardiac history, a list of other concomitant illnesses and an allergic history were required for entry into the study. All medications received before or during the procedure were also recorded as part of the study . No dosage of any medications prescribed for the treatment of augiua or other illnesses was withheld before the catheterization procedure . Sedation with diazepam and other agents administered for premeditation were prescribed by the physicians performing the procedures . It was recommended that 5,000 U of heparin be given to all patients at the time of the arterial puncture .
The ECO and arterial pressure were monitored continuously during the entire procedure. All patients underwent left ventriculography and selective injections of the right and left coronary arteries and bypass grafts, if present . For the left ventnculogram. 0.5 ml/kg of contrast medium was used, The sequence of the injections was determined by the physicians performing the catheterization . The amount of contrast medium used and the time and the site of every injection were recorded . As part of the study protocol, the ECG was also recorded before, during and continuously for the Ist 2 min after the first right coronary artery injection, the first left coronary artery injection and the left ventricuIngram .
Atthe end of the procedure, the patient was asked, "How did you feel during this study?" Questions concerning specific adverse reactions such as pain or nausea were not asked. All adverse reactions (such as symptoms or clinical manifestations of an embolic event, chest pain, dyspnea, arrhythmias, nausea, vomiting, bronchospasm or urticaria) noted by the investigators or reported by tho patients and the treatment, if any, of these conditions were recorded . The investigators were asked to grade the adverse reactions as mild (resolving spontaneously without treatment), moderate (requiring medication or other treatment but not additional hospitalization) or severe (requiting additional hospitalization and treatment) and to state if the adverse reaction was secondary to the contrast medium. Adverse reactions that occurred during or after injections of contrast medium and were not related to procedural techniques or other medications were attributed to contrast medium .
Statistics. The unpaired r test was used to compare baseline values between the two patient groups, and the Chi-square test was used to compare discrete variables (26) . The data in the text and tables arc presented as mean values '_ISD.
Results
Of the 500 patients included in this randomised mulli . center study, 2311 received ioxaglate and 250 received iopamidol . As shown in Table I , patient chars neristics of the two groups were similar except that the number of patients 'fable 1 with a history of allergy was significantly higher in the iopamidol group (p = 0 .01) .
Adverse reactions (Table 2) . Sixty-seven patients in the iexaglate group had 02 adverse events during the cathelerization procedure, whereas 40 patients in the iopamidel group had 50 adverse events (p < The adverse events attributed to the contrast medium were 58 in the ioxaglale group and 29 in the iopamidol group (p < 0.11) ( Table 2) . Except for the sensation of mild womth associated with an injection, the incidence of ail other adverse events listed in Table 2 was higher in the ioxaglate group than in the iopamidal group . All the adverse reactions attributed to contrast medium were classified as mild or moderate with the exception that one of the two cases of bronchospasm was graded as severe .
There were no deaths, serious ventricular arrhythmias, pulmonary edema or embolic events in either patient group. Heparin was given to all patients in this study ; 452 patients received 5,000 U of heparin at the beginning of the procedure, 38 patients received heparin doses of 2,000 to 10,000 U (mean 4,900 U) and 10 patients had received anlieuagulant therapy with intravenous heparin for clinical indications before the catheterization. The dosage used to maintain therapeutic partial thraarboplastin levels was continued throughout the agiographic procedure .
No patient in this study required cardiac pacing and there were no reports of heart block or significant hradyarrhythmias attributed to contrast medium . Only 6 of the 500 patients (2 in the ioxaglate group and 4 in the iopamidol group) received atropine, which was given as premedicalion or for a vagal episode that occurred during the arterial puncture.
Ilventy patients in the ioxuglate group had nuusea ur vomiting. whereas only 2 patients in the iopamidol grown had nausea . In the ioxaglate group, 7 of the 96 patients who received the initial injection of contrast tncdiaa during :efl ventricolography developed nausea or vomiting compared with 11 of 153 patients who had the ventriculogram at the end of the procedure (p = 0.73) . Thus, timing of the left ventriculogram, which requires a relatively large bolus injection, at the beginning or at the end of the procedure did not affect the incidence of this adverse reaction in ionagtaletreated patients.
In this report allergic-type adverse reeveors included itching, rash, urticaria, bronchospasm or aaaphylacloid shock. No patient in this study developed anaphylactoid shock. There were 16 allergic adverse reactions in the 250 patients receiving ioxnglare compared with 4 such responses in the 250 patients receiving iopamidol (p < 0 .01). Of these allergic rdscrse reactions, 15 of the 16 in the ioxaglote group were attributed to the contrast medium compared with only I of the 4 in the iopamidol group (p < 0 .0007) ( Table 2) . The remaining four allergic adverse reactions were attributed to protamine; all four such reactions involved a rash or orticaria and occurred within 5 to 15 min after intravenous administration of protamine. These events were attributed to the medication administered by the patient's physician .
History of allergy (Table 3) . Patients with a previous history of a reaction to radiographic contrast medium or iodine compounds were excluded from this study . However, in the iopamidol group 77 patients reported a history of other allergic responses: 3 had asthma, 72 had drug allergies, 2 had foodallergies, 2 had potlinosis and 2 had allergies to insect bites or stings. In the ioxaglate group 52 patients had a None of the 77 patients in the iopamidol group with a history of allergy had an allergic-typo adverse event attrib.
uted to the contrast medium . compared with 7 of the 52 patients in the ioxaglale group with such a hiv,ery (p = 0.001) (Table 3) . Thus, the incidence of an allergic adverse event in the patients receiving ioxee late was significantly higher in those with a history of allergy (13 .5%) than in the total group (b%) (p = 11 .111 1). Despite o significantly greater number of patients with a history of allergy in the iopamidol group, the incidence of allergic-type adverse events remained very law 10.4% in the total group and 0% in the group with a hste,p nlallergy) .
3':emcdication (Table 4) . Thepharmacotagicugentscommainly used for premedicntion, as well as the adverse events in each group, are listed in Table 4 . There was no difference between the two patient groups in the number of patients who received any of the specific agents used for premcdica- nonionic monomers such as iopamidol and iohexol loxaglate, an ionic dimer, has a relatively low osmolality comparable to that of iopamidol and iohexoL However. because of the high incidence of nausea and vomiting asso. dated with intravenous injections of ioxaglate, it was not included in the reported studies 129,221 Thus, the question remains whether many of the adverse reactions are related to the high osmolality o€the conventional ionic contrast media or to the ionic nature of the compounds. loangl de is widely used for arterial urigiographv . In addition, several reports (27, 28) have stated that the incidence of adverse reactions differs between intravenous and intraarterial angiography . Thus, the present study was performed to compare ioxaglate and iopamidol during cardiac angiography. Our findings agree with those of the large multicenterintravenous studies : that is-the incidcncc of the adverse reactions is significantly higher with ionic than with nonionic contrast media . Because both contrast media in our study had similar osmnlality, our data suggest that the molecular structure may play an important role in determining the side effects of the contrast media .
Adverse cardiac effects. The side tTectsofcontrasit media during cardiac angiography can be classified as cardiac, hemodynamic or systemic. In the present study we observed that the QT interval prolongation immediately after the coronary injection was more significant in the ioxaglate than in the iopamidol g roup. ST segment and T wave changes were also observed in the ioxaglate-treated patients : however, because placement of the ECG leads was not uniform in this multicenter study, it was not possible to quantitate changes in these variables . Other studies 123-25) have also reported that the ST segment, T wave changes and QT interval prolongation are significantly greater with ioxaglate than with nonionic contrast medium . The origin of these ECG alterations redlaius uncertain. 'I he results of several laboratory studies (5) (6) (7) 29) suggest that the calcinmchelating properties of the contrast medium may be an important fadvr associated with these ECG changes . The significance of these changes is also not known . Studies in animals (5, 30, 31) have shown that the ventricular fibrillatory threshold is inversely related to the QT interval prolongation after contrast medium injections . However . no patient in our study had ventricular tachycardia or fibrillation, With the conventional ionic contrast media, the incidence of this adverse event varies from 0 .6% to 13% (32.33) . Thus, these data suggest that the incidence of serious ventricular arrhythmias may even be lower for both iopamidol and ioxaglate .
Selective coronary angiography with the conventional ionic contrast media is often associated with bradyarrhythrnias and heart block (1,11, 34, 35) . No significant bradyarrhythmias attributed to contrast medium or heart block were reported in this study . This finding agrees with (hose of previously published reports (11 . [23] [24] [25] 34 ) from relatively small trials at single institutions ; that is, coronary injections GFRT7. FT Al -903 OV FRSE Ev ENTS WITH CONTRAST MEDIA of nonionic contrast mrrhcm or ioxaglate are not associated with significant increases in RR intervals .
Hnoadrnumic r rrabfes and mw,-dial contmrtility mere not measured in this study . However, there were no reports of pulmonary edema or significant hypotension during or immediately after the procedure . The osmnlality, of the contrast medium appears to play a major role in the hemodynamic alterations, such as transient hypotension and elevation of the left ventricular end-diastolic pressure that occur after intraarterial injections of contrast medium (1 . 3 .wt .18. 23 .5534-3b). Previous studies that have measured these hemodynamic indexes have shown that the changes produced during bolus left ventricular injections are similar for the nonionic monomers and the ionic dimer inxaglnte and that these changes are minimal compared with those induced by similar injections of the conventional ionic monomer agents Q1,18,23,25,34,36-38) . Animal studies (39 .401 assessing myocardial contractility have demonstrated that the negative inotropic effects associated with injections of the conventional ionic contrast media are significantly less with ioxaglate and that the nonionic contrast media have a small positive inotropic effect .
Nausea and vomiting. Nausea and vomiting represent a systemic chemotoxic effect of contrast media . A possible explanation for this side effect is that the contrast molecule binds to protein and results in enzyme inhibition of cholineutcease (2,41,42) . In vitro experiments (41) have shown that nonionic contrast media such as iopamidol and iohexol produce less inhibition of cholinesterase than does ioxaglate. Intravenous injections of ioxaglate are often associated with a high incidence (25% to 37%) of nausea and vomiting (42) (43) (44) . to this intraartcriat randomized study, nausea or vomiting, or both. occurred in 8% of the patients receiving ioxaglate . In the iopamidot gr,m.tp, nausea only occurred in 0.81A (p c O,INJ03) . Other studies (21.75,!5) that used ioxaglate for intaarterial proCedates have also reported a higher incidence of [his adverse reaction.
Alle m rynn adverse reaclions, Allertdc-type or "anaphylactoid" adverse reactions can be the most severe or lifethreatening adverse reactions that result from intravascular injections of contrast medium-In this study two patients developed brotlchospasm, classified as severe in one and as moderate in the other ; loth patients were in the ioxaglate group . No patient developed anaphylactoid shack or circulatory collapse . In addition to the two cases of brcnchospasm, there were 13 other mild to moderate allergic-type adverse reactions in the ioxaglate soup compared with only I in the iopamidol group (Table 2) .
The eruct mechanism jar these allergic-type adverse reactions it rtnrlear (46). The classic antigen-antibody im• mane reaction has been postdated (47,48) but not proved . Anticontrast medium antibodies have not been detected in patients with adverse reactions (12) . Similarly, a high percentage of these patients do not experience recurrence of the adverse reaction during subsequent angiographic procedures (49) . Contrast media can induce histamine and serotonin GERTZ Li AL. ADVERSS LVEN'IN WITH CUNIIIAS'I' MEDIA release (50, 51) and can also activate the cimplement and coagulation systems (17) . Contact-system activators are present in vascular endothelium and mast cells ; release of these activators by contrast media as well as other hyperosmolar agents can result in a series of proleolytic events leading to the production of bradykinins 115,521. Ialli and (rcenslreet (16) hypothesized that many of the adverse reactions are secondary to anxiety and are controlled by the central nervous system. Whether one or several of these mechanisms are responsible for the allergic-type adverse reactions remains to be determined, However . the understanding of the pathuphysiolugy of these events may became very important in the selection of or the future development of contrast media .
Several clinical studies (22. 27 .53-57) have shown that the incidence of adverse reactions to contrast medium is two to four times greater in patients with asthma or a history of any allergy than in patients without these conditions . Among the ioxaglate-treated patients in our study, 13 .5% of those with asthma or a known allergy had au allergic-lyre adverse event compared with 4% of those without these conditions . However, although more patients with a history of asthma or allergy were receiving iopamidol, only one allergic-type adverse reaction occurred in this group and the affected patient had no known allergy . These data strongly suggest that patients with asthma or a history of an allergy are at an increased risk for an adverse event during angiography with ioxaglate and that the use of a nonionic contrast medium may reduce the risk in such patients . Several previous studies (13) (14) (15) (16) (17) have implied that the high osmolality of the contrast medium may be responsible for many of these adverse events . However, the similar osmolality of the two contrast media in our study suggests that the ionic nature of the compound may play an important role in precipitctirg these adverse events.
Premeditation with various phorinaealogic agents has been advocated to reduce the risk of Ciese adverse events . These agents include steroids 158 .591, diphelhydramine or H l -receptor antagonist (60), diazepam (16, 61 ) and, most recently, H,-receptor antagonist (62, 63) . Controversy exists as to the efficacy of these medications in reducing the incidence and the severity of the adverse events induced by contrast medium (49,1,63-66)_ In our study the number of patients receiving premeditation did not differ significantly between the immolate and iopamidol groups (Table 4) . Although our study was not designed to assess the effects of the various medications used for pretreatment, the data suggest that pretreatment with diphenhydramine or sedation with diazepam does not completely protect against an allergic-type adverse reaction to ioxaglate . In addition, cases have been reported (1,65,67,68) of severe anaphylaxis with circulatory collapse occurring with the use of conventional ionic contrast media and ioxaglate after premeditation with diphenhydramine and steroids . Rapoport et al . 164) described six patients who developed a severe anaphylactoid reaction to conventional high osmolality ionic contrast medin despite premeditation ; several days after the untoward event, these patients underwent repeat angiagraphy with use of a nonionic contrast medium (metrizamide) and none of the six had an adverse event with the nonionic agent, Hollas (68) reported similar findings in 17 patients with a previous well documented allergic-type adverse reaction occurring with the use of conventional ionic contrast media; with iohexol as the contrast medium only I of these 17 patients developed a skin reaction that occurred very [are (that is, 24 h) after the procedure . These data suggest that the incidence of allergictype adverse reactions is signifcnntly lower with nonionic than with ionic contrast media . Large randomized prospective studies are needed to determine whether the incidence of adverse reactions with ioxaglate after pretreatment is equal to or better than that with a nonionic contrast medium .
Clinical implications. This multicenter, prospective . randomized study shows that ioxaglate and iopamidol are safe and well tolerated during cardiac angiogimphy . The incidence of mild to moderate adverse reactions attributed to cottlcast medium w,ix higher with the ionic dimerioxaglate than with the nonionic contrast medium iopamidol. The alergic-type adverse teato ionswere also higher in the ioxaglate-treated patients (6%) than in the iopamidol group (0.4%) (p < 0.0007). Among patients treated with ioxaglate, those with asthma or a history of a known allergy had a 3.4 times greater incidence of an allergic-type adverse event than did patients without a known allergy . None of the patients with asthma or a known allergy receiving iopamidol had an allergic-type adverse event . Thus, these data suggest that a nonionic contrast medium should be used for cardiac angiography to avoid allergic-type adverse reactions, especially in patients with a known allergy .
